Human CD47 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Human CD47 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityHuman CD47
Clone[8H7]
Host SpeciesMouse
Reactive Specieshuman.
IsotypeIgG1,k
FormatProtein G purified
Size0.5 mg
Concentrationn/a
ApplicationsBlocking (BL)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionReactive with recombinant and native human CD47. CD47 is a ubiquitously expressed 50 kDa transmembrane protein with an extracellular N-terminal IgV domain. CD47 inhibits phagocytosis through interaction with signal regulatory protein a (SIRPa) on macrophages and other phagocytic cells. Normal cells, especially cells in brain tissue, placenta, prostate, bladder and fallopian tube, expressed abundant CD47. Aged erythrocytes and spontaneous apoptotic cells express less CD47 and are more likely been phagocytized. CD47 expression in many cancer cells are elevated. It is believed that CD47 is a self marker that helps cancer cells to escape from immunity. CD47 is also a receptor for thrombospondin-1 (TSP-1) and integrin. It may play a role in an
ImmunogenImmunogen: Human cell expressed recombinant Human CD47 (Gln19-Pro139) with a poly-histidine tag at the C-terminus. Accession #: Q08722. Light Chain: Kappa. Fusion Myeloma: Sp2/0-Ag14. Target Protein: Human CD47
Other Names[mAb Human CD47; Mouse to human CD47, Clone 8H7; Mouse (mAb) to human CD47], [CD47; CD47; IAP; OA3; MER6; MER6; IAP]
Gene, Accession #[CD47], Gene ID: 961, NCBI: CEJ95640.1
Catalog #MBS590087
Price$490
Order / More InfoHuman CD47 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.